Pharmacological targeting of the protein synthesis mTOR/4E‐BP1 pathway in cancer‐associated fibroblasts abrogates pancreatic tumour chemoresistance

Publisher： John Wiley & Sons Inc

E-ISSN： 1757-4684|7|6|735-753

ISSN： 1757-4676

Source： EMBO Molecular Medicine, Vol.7, Iss.6, 2015-06, pp. : 735-753

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer

By  

Molecular Carcinogenesis, Vol. 899-1987, Iss. 10, 2015-10 ,pp. : 1086-1095

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer

By  

Molecular Carcinogenesis, Vol. 54, Iss. 10, 2015-10 ,pp. : 1086-1095

John Wiley & Sons Inc

Access to resources Recommend Favorite

Silibinin prevents prostate cancer cell‐mediated differentiation of naïve fibroblasts into cancer‐associated fibroblast phenotype by targeting TGF β2

By  

Molecular Carcinogenesis, Vol. 54, Iss. 9, 2015-09 ,pp. : 730-741

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

By  

EMBO Molecular Medicine, Vol. 7, Iss. 8, 2015-08 ,pp. : 1063-1076

John Wiley & Sons Inc

Access to resources Recommend Favorite

Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β‐catenin‐EGFR‐PI3K‐Akt‐mTOR signaling pathway

By  

Molecular Carcinogenesis, Vol. 57, Iss. 2, 2018-02 ,pp. : 201-215

John Wiley & Sons Inc

Access to resources Recommend Favorite